Novel β-lactam/β-lactamase inhibitor combinations and cefiderocol may play a part in the treatment of infections caused by Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and Burkholderia cepacia complex.
Sarah L. Spitznogle, PharmD*
Advertisement
Articles by Sarah L. Spitznogle, PharmD*
Advertisement
Latest Updated Articles
- Evaluating the Role of New Beta-Lactam Agents for Uncommon Pathogens
Published: October 14th 2019 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
2
One Third of Chronic Hepatitis B Patients Are Lost to Follow-Up
3
Antibiotic Shows Promise in Treating Gram-Positive Pneumonia, Including in High-Risk Patients
4
DOOR Analysis Shows Antibiotic Matches Standard Therapy in Effectiveness
5
